Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials)

Author： Ahmed Shaheeda Antman Elliott Murphy Sabina Giugliano Robert Cannon Christopher White Harvey Morrow David Braunwald Eugene

Publisher： Springer Publishing Company

ISSN： 0929-5305

Source： Journal of Thrombosis and Thrombolysis, Vol.21, Iss.2, 2006-04, pp. : 119-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Fibrinolysis for ST-segment elevation myocardial infarction (STEMI) reduces mortality, but its relative efficacy and risks are age-dependent. We aimed to quantify the outcomes of fibrinolysis and adjunctive antithrombin therapy for STEMI stratified by age.Methods: We performed a meta-analysis of 11 published (1992–2001) randomized clinical trials of fibrinolysis in STEMI (sample size ≥3000, no age limit, no placebo-controlled arms) identified by MEDLINE through June 2005. Event rates and odds ratios (OR) in elderly vs. younger patients were calculated for mortality, intracranial hemorrhage (ICH) and total stroke (CVA). Elderly patients were defined as ≥75 years (GUSTO I, TIMI 9B, GUSTO III, COBALT, ASSENT-2, InTIME-II TIMI-17, ASSENT-3, GUSTO V, and HERO-2), except when defined as >65 or ≥70 years by the study (INJECT and ISIS-3).Results: Elderly (n = 24 531) vs. younger (n = 123 568) patients had increased rates of mortality (19.7% vs. 5.5%), ICH (1.4% vs. 0.5%) and CVA (3.5 vs. 1.2%) by 30–35 days; the excess risk for these events was substantial (OR mortality 4.37, 95% CI 4.16–4.58; ICH 2.83, 2.47–3.24; CVA 2.92, 2.62–3.25; p < 0.001 for all).Conclusions: Despite established mortality reductions with fibrinolysis for STEMI, elderly compared with younger patients, still have a three to four fold increased risk of mortality and adverse events when treated with fibrinolysis and antithrombin therapy in the modern era. These robust estimates of the anticipated rates for mortality, ICH, and CVA can be used as benchmarks to monitor the efficacy and safety of therapies in ongoing and newly completed clinical trials.

Related content

Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis

By Ahmed Shaheeda

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 4, 2011-05 ,pp. : 493-500 (8)

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of Approaches to Revascularization in Patients With Multivessel Coronary Artery Disease Presenting With ST‐Segment Elevation Myocardial Infarction: Meta‐analyses of Randomized Control Trials

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 12, 2015-12 ,pp. : n/a-n/a (NaN)

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metformin and Myocardial Injury in Patients With Diabetes and ST‐Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 10, 2015-10 ,pp. : n/a-n/a (NaN)

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of Gender and Other Factors as Predictors of Not Receiving Reperfusion Therapy and of Outcome in ST-Segment Elevation Myocardial Infarction

By Cohen Marc Gensini Gian Maritz Frans Gurfinkel Enrique Huber Kurt Timerman Ari Santopinto Jose Corsini Giancarlo Terrosu Pierfranco Joulain Florence

Journal of Thrombosis and Thrombolysis, Vol. 19, Iss. 3, 2005-06 ,pp. : 155-161 (7)

Springer Publishing Company

Access to resources Recommend Favorite

Multiple biomarkers for the prediction of short and long-term mortality after ST-segment elevation myocardial infarction: the Amsterdam Groningen collaboration

By Damman Peter

Journal of Thrombosis and Thrombolysis, Vol. 36, Iss. 1, 2013-07 ,pp. : 42-46 (5)

Springer Publishing Company

Access to resources Recommend Favorite